Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Flucloxacillin sodium
Bristol Laboratories Ltd
J01CF05
Flucloxacillin sodium
250mg
Oral capsule
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 05010102; GTIN: 5060013942402
SAME SIZE ARTWORK 240 x 160 mm Front 24 mm 240 mm 160 mm IXXXXXX PACKAGE LEAFLET: INFORMATION FOR THE USER FLUCLOXACILLIN 250MG CAPSULES FLUCLOXACILLIN 500MG CAPSULES (Flucloxacillin) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Flucloxacillin Capsules are and what are they used for 2. What you need to know before you take Flucloxacillin Capsules 3. How to take Flucloxacillin Capsules 4. Possible side effects 5. How to store Flucloxacillin Capsules 6. Contents of the pack and other information 1. WHAT FLUCLOXACILLIN CAPSULES ARE AND WHAT ARE THEY USED FOR The name of the medicine is Flucloxacillin 250mg or 500mg Capsules which will be referred to as Flucloxacillin Capsules throughout this leaflet. The active ingredient is flucloxacillin. Flucloxacillin belongs to a group of medicines called Beta-lactamase resistant penicillins. It is an antibiotic used to treat infections by killing the bacteria that cause them. Flucloxacillin is used to treat the following infections in adults, and children aged 2-10 years. It can also be used in children less than 2 years of age. Your doctor will adjust the dose depending on the age of the patient • skin and soft tissue infections (including boils, abscess, carbuncles, ulcers, infected eczema and acne, wounds and burns. • chest infections (including pneumonia and lung abscess) • ear, nose and throat infections including tonsils (tonsillitis), sinuses (sinusitis), pharynx (pharyngitis) and ear infections (otitis media and otitis externa). • Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Flucloxacillin 250mg Capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 250 mg flucloxacillin as flucloxacillin sodium. Excipient(s) with known effect: Each capsule contains 1.60 mg of methyl parahydroxybenzoate (E218) and 0.90 mg of propyl parahydroxybenzoate (E216). For the full list of excipients, see Section 6.1. 3 PHARMACEUTICAL FORM Capsules Blue cap/blue body capsule printed with “F 250” and containing a white, free flowing powder. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Flucloxacillin is an isoxazolyl penicillin of the β -lactam group of antibiotics which exerts a bactericidal effect upon many Gram-positive organisms including β -lactamase-producing staphylococci and streptococci. Flucloxacillin Capsules are indicated for the treatment of infections due to flucloxacillin sensitive gram-positive organisms, including β -lactamase- producing staphyloccoci and streptococci. Typical indications include: _Skin and soft tissue infections: _ Boils Abscesses Cellulitis Infected skin conditions, e.g. ulcer, eczema, and acne Infected burns Protection for skin grafts Carbuncles Impetigo Furunculosis Infected wounds _Respiratory tract infections: _ Pneumonia Sinusitis Tonsillitis Lung abscess Pharyngitis Quinsy Empyema Otitis media and externa _Other infections caused by flucloxacillin-sensitive organisms: _ Osteomyelitis Meningitis Urinary tract infection Endocarditis Enteritis Septicaemia Flucloxacillin is also indicated for use as a prophylactic agent during major surgical procedures when appropriate; for example cardiothoracic and orthopaedic surgery. Parenteral usage is indicated where oral dosage is inappropriate. Consideration should be given to official local guidance (e.g. national recommendations) on appropriate use of antibacterial agents. Susceptibility of the causative organism to the treatment should be tested (if possible), although therapy may be initiated before the results are available. 4.2 PO Read the complete document